Navigation Links
Progress toward an Alzheimer's drug that saves brain cells

Leuven − VIB scientists connected to the K.U.Leuven have identified a molecule that can form the basis for a new therapy for Alzheimer's disease. This is the first step toward a medicine that could actually stop the progress of Alzheimer's. Existing medicines can at best limit the loss of memory during the first phases of the disease. The authoritative journal Science is publishing the results of this research. A first step, however, is still a long way from an approved drug − even if everything goes well, it will be another 15 years before the medicine becomes available.

Alzheimer's disease

Alzheimer's disease is the most prevalent form of dementia in the Western world. The disease's harmful effects on memory and mental functioning make it one of the most terrifying syndromes. It is estimated that, by 2010, our country will have more than 150,000 Alzheimer's patients. At present, this disease is still incurable. Today's medicines for Alzheimer's patients sustain the memory functions for a short time, but they do not stop the brain's cells from dying off.

Plaques and the γ-secretase complex

A typical characteristic of the brains of Alzheimer's patients is the presence of amyloid plaques, which are abnormal accumulations of the β-amyloid protein between the neurons. The sticky β-amyloid arises when the amyloid precursor protein is cut into pieces incorrectly.

The γ-secretase complex − which cuts proteins at a specific place − plays a major role in the creation of these plaques. However, this complex (group of proteins that work together) is also involved in the regulation of a series of other essential proteins such as Notch, which plays a crucial role in the development of an embryo. This is why many of the medicines in development that act on the whole γ-secretase complex run up against toxic side effects.


Under the direction of Bart De Strooper, and in collaboration with researchers in other countries, Lutgarde Serneels, Jrme Van Biervliet and their colleagues have been studying the γ-secretase complex in a variety of tissues. They have now been able to demonstrate that the complex assumes a different shape and function according to the tissue in which the secretase is active. For their research on Alzheimer's disease, the researchers have used mouse models. They have found that deactivating the variant, Aph1B γ-secretase, in Alzheimer mice leads to reduced formation of the plaques, without any harmful side effects.

Importance of the research

With this discovery, the researchers are once again opening a way toward the development of medicines that deactivate γ-secretase. By concentrating on a variant of the complex that cuts proteins specifically in the brain − the Aph1B γ-secretase complex − the formation of the plaques can be prevented, while the other functions of γ-secretase are not affected. This raises hopes for a drug that, for the first time, will succeed in stopping Alzheimer's disease. Furthermore, because the toxic side effects have been cut away, it could also be administered preventively to persons with a risk of Alzheimer's. However, such a medicine will still require at least a good 15 years of further research and development.

Given the fact that γ-secretase is also involved in the onset of certain cancers, research on the various variants of γ-secretase can lead to new insights into these diseases as well.


Contact: Evy Vierstraete
VIB (the Flanders Institute for Biotechnology)

Related biology technology :

1. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
2. Nventa updates progress of cervical dysplasia trial with new HspE7
3. AIM-Quoted Verona Pharma Progresses Anti-Asthma Drug Studies
4. Dynavax Reports Progress in Lupus Program With Inhibitor of TLR7 and TLR9
5. Significant Progress Made in Nations Preparedness to Respond to Public Health Emergencies; But Gaps in Critical Areas Threaten Overall Readiness
6. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
7. Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress
8. Flurizans Effect in Delaying Progression From Mild Cognitive Impairment to Alzheimers Disease is Superior to That of Aricept
9. Phlo Affiliate Reports Progress in New York City Metropolitan Area Roll-Out
10. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
11. Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress
Post Your Comments:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , ... June 23, 2016 , ... STACS DNA Inc., ... Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field ... DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding ...
(Date:6/23/2016)... Andrew D Zelenetz ... Published recently in Oncology ... touchONCOLOGY, Andrew D Zelenetz , discusses the ... is placing an increasing burden on healthcare systems ... With the patents on many biologics expiring, interest ...
Breaking Biology Technology:
(Date:6/15/2016)... 2016 Transparency Market Research ... Market by Application Market - Global Industry Analysis Size Share ... the report, the  global gesture recognition market  was ... is estimated to grow at a CAGR of ... Increasing application of gesture recognition technology ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... project, for the , Supply and Delivery of ... Infrastructure , to Decatur , ... Management Solutions. Numerous renowned international vendors participated in the tendering ... selected for the most compliant and innovative solution. The contract ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
Breaking Biology News(10 mins):